search button
Open Access

Expression of immune regulatory factors, chemokines and growth factors in differentiated gastric cancer cells treated with an anticancer bioactive peptide combined with oxaliplatin

  • Authors:
    • Xian Li
    • Jiaqi Peng
    • Xiulan Su

  • View Affiliations

  • Published online on: December 6, 2023     https://doi.org/10.3892/mco.2023.2707
  • Article Number: 9

  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Gastric cancer is one of the most common malignant tumors of the digestive system. An anticancer bioactive peptide (ACBP) was previously shown to have an important role in inhibiting the differentiation of the MKN‑45, N87 and GES‑1 cell lines. However, to date, research on the effects of inflammatory factors in MKN‑45, N87 and GES‑1 cell lines after treatment with ACBP combined with oxaliplatin (OXA) has not been performed. To investigate the expression of immune regulatory factors, tumor growth factors and chemotactic factors in differentiated gastric cancer cells treated with ACBP combined with OXA, the expression of cytokines, including interleukin (IL)‑1β, IL‑1 receptor antagonist, IL‑2, IL‑4, IL‑6‑10, IL‑12, IL‑13, IL‑15, IL‑17, Eotaxin, basic fibroblast growth factor (bFGF), granulocyte‑macrophage colony‑stimulating factor (GM‑CSF), interferon (IFN)‑γ, monocyte chemoattractant protein (MCP)‑1, IFN‑γ‑induced protein‑10, macrophage inflammatory protein (MIP)‑1α, platelet‑derived growth factor (PDGF)‑BB, MIP‑1β, regulated upon activation, normal T cell expressed and presumably secreted, TNF‑α and VEGF, was assessed with cell experiments using the Bio‑Plex ProT Human Cytokine 27‑plex Assay. The results indicated that immune regulatory factor, tumor growth factor and chemotactic factor expression levels were different after treatment with ACBP alone or ACBP combined with OXA. IFN‑γ, IL‑1β, IL‑17, IL‑9, IL‑10, IL‑15, bFGF, GM‑CSF and PDGF‑BB expression was decreased in MKN‑45 and N87 cells after ACBP treatment (P<0.01) and ACBP+OXA treatment (P<0.01) compared with the control cells, which indicated that ACBP inhibited tumor growth by regulating these cytokines, and the combination treatment inhibited tumor growth by regulating these cytokines. MIP‑1β, MCP‑1 and IL‑13 expression was decreased in MKN‑45 and N87 cells after the combination treatment compared with ACBP treatment alone, which indicated that ACBP combined with OXA was able to inhibit tumor growth by regulating these cytokines, while the mechanism of action of the ACBP and OXA is actually different, e.g. for OXA, this would be to cause DNA damage response. Therefore, the ACBP and OXA combination treatment may be closely associated with tumor progression and metastasis with immunological competence by MCP‑1, MIP‑1β and IL‑13 expression.
View Figures
View References

Related Articles

Journal Cover

January-2024
Volume 20 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 1.2
  • Ranked
    (total number of cites)
  • CiteScore: 2.6
  • CiteScore Rank: Q3: #242/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.693
  • SCImago Journal Rank (SJR): 0.393
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Li X, Peng J and Su X: Expression of immune regulatory factors, chemokines and growth factors in differentiated gastric cancer cells treated with an anticancer bioactive peptide combined with oxaliplatin. Mol Clin Oncol 20: 9, 2024
APA
Li, X., Peng, J., & Su, X. (2024). Expression of immune regulatory factors, chemokines and growth factors in differentiated gastric cancer cells treated with an anticancer bioactive peptide combined with oxaliplatin. Molecular and Clinical Oncology, 20, 9. https://doi.org/10.3892/mco.2023.2707
MLA
Li, X., Peng, J., Su, X."Expression of immune regulatory factors, chemokines and growth factors in differentiated gastric cancer cells treated with an anticancer bioactive peptide combined with oxaliplatin". Molecular and Clinical Oncology 20.1 (2024): 9.
Chicago
Li, X., Peng, J., Su, X."Expression of immune regulatory factors, chemokines and growth factors in differentiated gastric cancer cells treated with an anticancer bioactive peptide combined with oxaliplatin". Molecular and Clinical Oncology 20, no. 1 (2024): 9. https://doi.org/10.3892/mco.2023.2707